SCYNEXIS Inc SCYX

Healthcare Biotechnology

SCYNEXIS, Inc. is a biotechnology company. It is pioneering medicine to overcome and prevent difficult-to-treat and drug-resistant infections. It develops antifungal platform fungerps, a novel class of antifungal agents called triterpenoids, that are structurally distinct glucan synthase inhibitors and have generally shown in vitro and in vivo activity against a range of human fungal pathogens, such as Candida and Aspergillus genera, including multidrug-resistant strains, and Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and common mucorales species. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the fungerp family, including SCY-247, in preclinical stages of development. The United States Food and Drug Administration approved BREXAFEMME for treatment of patients with vulvovaginal candidiasis, also known as vaginal yeast infection, and for the reduction in the incidence of recurrent vulvovaginal candidiasis.

NDAQ:SCYX - Post by User

SCYNEXIS Inc > 2 Weeks Left...

<< Previous

Bullboard Posts

Next >>

Comment by JonathanJSmithon Jun 02, 2021 7:26am

50 Views

Post# 33309254

RE:RE:2 Weeks Left...

Yeah, everyone's in waiting mode. I think the company has 24 hours to release material information - assuming they've received some.

Personally, based on data the drug should be approved. My only concern is the vexing "we couldn't inspect the manufacturing site(s) due to Covid-19 travel restrictions" comment; if such comment is forthcoming, the company could be looking at additonal wait time (months' worth most likely).

Fingers crossed! I'm quite bullish however it plays out.

Cheers,

JJ

<< Previous

Bullboard Posts

Next >>

StockTalk | Gold Report: Government risk, green flags and a tax benefit